Enovis 3rd Quarter 2026 Earnings Call - ENOVIS CORP

Financial Performance:

• Third-quarter revenue was $559 million, reflecting 2% year-over-year growth on a reported basis and 5% organic growth.
• Adjusted gross margins expanded 60 basis points to 60.9%, driven by favorable product mix, operational productivity, and $8 million in tariff refunds (partially offset by $3 million in inflationary costs).
• Adjusted EBITDA margin reached 18.5%, a 120 basis point improvement year-over-year.
• Adjusted earnings per share (EPS) were $0.88, up 17% from the prior year.
• Free cash flow totaled $35 million in the quarter, bringing year-to-date free cash flow to $37 million ($50 million improvement vs. prior year).
• Year-to-date free cash flow conversion remains on track to exceed the 25% target for the full year 2026.
• Net leverage stood at 2.9 times at quarter-end, remaining below the 2.5–3.5 times target range; expected to rise by 0.5x upon closing the Essential Robotics acquisition.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance narrowed to $2.32–$2.35 billion.
• Full-year organic growth is expected to be approximately 5%.
• Adjusted EBITDA guidance raised to $428–$438 million; Adjusted EPS range raised to $3.58–$3.79.
• Q4 outlook anticipates modest acceleration in both segments, driven by harvest activities, shoulder product momentum, continued Nebula conversions, and new P&R product launches.
• 2027 outlook assumes a step-up in free cash flow conversion to at least 50% and $100 million in annual cash generation.
• Future guidance includes a $4 million investment in R&D talent for robotics integration and a $1 million currency headwind for Q4.

Business Segments and Product Lines:

• Recon (Orthopedics): Delivered 6% organic growth (5% in US, 8% internationally).
  • US Extremities grew 5%; Hips and Knees grew 3%. Nebula is now the top-selling stem, with over 80% of new sets going to competitive users.
  • Shoulder grew double-digits internationally, with the first Arvus cases completed in Europe; US shoulder growth returned to high single digits.
  • ARG (robotics) continues to drive growth in extremities, now past its one-year anniversary.
• P&R (Physical Rehabilitation): Delivered 3% organic growth (5% in US).
  • Global bracing grew 3%, supported by spine, core, and lower extremity segment mix.
  • Recovery Science saw double-digit growth driven by Regen product launches, specifically the Manifuse transition.
  • Dr. Comfort divestiture headwind was a one-time factor affecting this year-over-year comparison.

Market and Competitive Landscape:

• The US extremities market remains volatile, with softness noted in hips and knees; the company is focusing on market share gains rather than total market volume.
• International Recon growth was impacted by challenging dynamics in Western Europe and the Middle East conflict (100 bps headwind to international growth).
• Anovus holds a leading global position in shoulders (number three globally, number two internationally) and is aggressively converting competitive accounts.
• The ASC (Ambulatory Surgical Center) channel represents a strategic growth area, with ~25% of primary knees and ~20% of hips currently performed there.
• Competition includes new knee launches by rivals and the absence of impactors in some competitor hip systems, which Anovus leverages with its triple-tapered collared stem.

Risks and Challenges:

• Geopolitical instability in the Middle East continues to weigh on growth and increase inflationary pressures on raw materials, freight, and distribution.
• Volatility in the US surgical market, including potential patient delays due to economic factors or surgical schedule disruptions.
• Foreign currency headwinds (30 bps in Q3) and the integration risks associated with the pending acquisition of Essential Robotics.
• Regulatory or reimbursement pressures in international markets, specifically France and Germany within the P&R segment.

Management Commentary and Tone:

• Management expressed confidence in the company's resilience and ability to gain market share despite a "choppy" environment.
• Tone was optimistic regarding the pending acquisition of Essential Robotics, viewing it as a "meaningful contributor" to future above-market growth.
• CEO Damian McDonald emphasized controlling "controllables" through disciplined sales force training and targeted account acquisition.
• CFO Ben Berry highlighted improved cash generation providing flexibility for capital allocation, including the new $200 million share repurchase program.

Analyst Questions and Answers:

• Market Softness: On U.S. hip/knee softness, management confirmed market volatility but reiterated a focus on share gain; they do not guide on anatomy-specific growth rates due to dynamics.
• Q4 Growth Drivers: Q4 growth acceleration is attributed to an extra selling day (+150 bps), normal seasonality, and product momentum.
• Essential Robotics Integration: Early feedback from customers and reps is highly positive regarding the "ecosystem" approach (combining robotics with enabling tech/navigation); deal expected to close by year-end.
• Foot and Ankle: Q3 was slightly softer but expected to rebound; the long-term outlook remains high single-digit growth.
• Capital Allocation: The new share repurchase program is described as opportunistic and disciplined, intended to capture value while maintaining leverage targets; debt reduction remains a priority but buybacks are a viable tool for value creation.
• Gross Margins: Q3 margin expansion included tariff refunds; future margins are expected to expand as the Recon portfolio grows, despite mix pressures.

Other Key Points:

• Anovus announced a new $200 million share repurchase program authorized by the Board.
• The acquisition of Essential Robotics is binding; Works Council consultation is complete, with integration planning underway to accelerate the knee robot launch (targeted within two years) and shoulder robot launch.
• P&R portfolio now has over 50% of products growing at mid-single digits or higher.
• MotionMD software maintains a 99% customer satisfaction rating, driving stickiness through inventory reduction and claims processing speed.